Barba, Lorenzo
Vollmuth, Christoph
Abu-Rumeileh, Samir
Halbgebauer, Steffen
Oeckl, Patrick
Steinacker, Petra
Kollikowski, Alexander M.
Schultz, Cara
Wolf, Judith
Pham, Mirko
Schuhmann, Michael K.
Heuschmann, Peter U.
Haeusler, Karl Georg
Stoll, Guido
Neugebauer, Hermann
Otto, Markus
Funding for this research was provided by:
German Research Council (Project No. 413657723)
Medical Faculty of Halle University (No. CS22/06)
Martin-Luther-Universität Halle-Wittenberg
Article History
Received: 22 August 2023
Accepted: 17 November 2023
First Online: 28 November 2023
Competing interests
: KGH reports speaker´s honoraria, consulting fees, lecture honoraria and/or study grants from Abbott, Alexion, Amarin, AstraZeneca, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Medronic, Pfizer, Portola, Premier Research, Sanofi, SUN Pharma, and W.L. Gore & Associates. M. Otto gave scientific advice for Fujirebio, Roche, Biogen, and Axon; the foundation of the state Baden-Wuerttemberg handed in a patent for the measurement of beta-synuclein and relevant authors are M. Otto, S. Halbgebauer, and P. Oeckl. All other authors declare no competing interests.